Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Advaxis, Inc.
University of Washington
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
HealthPartners Institute
Valerio Therapeutics
Valerio Therapeutics